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Background: Breast cancer-related mortality increases annually. The efficacy of current breast cancer treatments is
limited, and they have numerous side effects and permit high recurrence. Patients with estrogen receptor (ER)-negative
or triple-negative breast cancer are particularly difficult to treat. Treatment for this type of cancer is lacking, and its
prognosis is poor, necessitating the search for alternative treatments.
Methods: This study screened Chinese herb Hibiscus syriacus extracts and identified a novel anti-cancer drug for
patients with ER-negative breast cancer. The inhibitory effects on cell viability and migration were evaluated for
each compound, and the molecular regulatory effects were evaluated on both mRNA and protein levels.
Result: We found several triterpenoids including betulin (K02) and its derivatives (K03, K04, and K06) from H.
syriacus inhibited human triple-negative breast cancer cell viability and migration but revealed smaller cytotoxic
effects on normal mammalian epithelial cells. Betulin and its derivatives induced apoptosis by activating
apoptosis-related genes. In addition, they activated p21 expression, which induced cell cycle arrest in breast cancer
cells. Betulin (K02) and betulinic acid (K06) had stronger inhibitory effects on cell viability and migration than K03
and K04.
Conclusions: H. syriacus extracts might inhibit breast cancer cell viability and induce apoptosis by activating
p53 family regulated pathways and inhibiting AKT activation. H. syriacus extracts may provide important insight
into the development of novel alternative therapies for breast cancer.
Keywords: Hibiscus syriacus, Betulin, Breast cancerBackground
Breast cancer is one of the most common cancers in fe-
males worldwide. Approximately 500,000 people die an-
nually from breast cancer, and about one out of eight
females are diagnosed with breast cancer [1]. Currently,
the main treatment for breast cancer is surgery, along
with radiotherapy, chemotherapy, hormone, and immuno-
logical treatment. The efficacy of current treatments for* Correspondence: jaryiho@gmail.com; cpyupath@yahoo.com.tw
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unless otherwise stated.breast cancer is limited. In addition to side effects, the risk
of recurrence is high. Clinically, 70% of breast cancer pa-
tients are positive for the estrogen receptor (ER) in the
tumor. After treatment with tamoxifen, the death rate and
recurrence rate is reduced by 50% and 25%–30%, respect-
ively. However, one-third of patients showed recurrence
within fifteen years after tamoxifen treatment, and the
cancer cells’ failure to express estrogen receptor (ER) is
one of the most important reasons [2]. Furthermore,
10%–15% of breast cancers are of the triple-negative sub-
type. Treatment is lacking for patients with this type of
breast cancer, and their prognosis is poor [3]. Thus, treat-
ment for breast cancer has been a difficult issue.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hsu et al. BMC Complementary and Alternative Medicine  (2015) 15:65 Page 2 of 9Many patients seek natural, traditional treatments to
alleviate or improve breast cancer and the side effects
caused by treatment. Herbal therapy has been used for
thousands of years, and there are several organisms that
provide a source of anti-cancer drugs in nature. Several
Chinese herbal medicines are effective against diseases,
but most of the effects and mechanisms of action are
not scientifically supported. The effect of Chinese herbal
medicines on cancer has become a hot research topic.
For instance, EGCG extracted from green tea inhibits
the growth of pancreatic cancer cells [4]. EGCG also in-
duces MCF-7 cells towards p53-related apoptosis in
breast cancer cells [5]. Intake of EGCG extracted from
green tea reduces the occurrence of head and neck can-
cer [6]. Besides, huanglian increases the inhibition of
cell cycle-related protein expression, leading to sup-
pressed growth of cancer cells [7]. The popular sporophore
extract from Antrodia cinnamomea reduces the invasive
ability of hepatoma cells by inhibiting the NF-κB signal
transduction pathway [8]. Betulin, isolated from H. syriacus
[9], is a natural triterpene that has anti-cancer effects, but
its mechanism of action remains unclear [10,11].
H. syriacus is found in tropical and subtropical areas.
The flower, fruit, root, stem, and skin of H. syriacus all
show pharmaceutical effects and have been widely used
as medicinal treatment materials in Asia. The flower
from H. syriacus is used for the treatment of dysentery,
vaginal discharge, and hemorrhoids; the fruit is used as
an expectorant and for cough and neurological head-
ache; the skin has antipyretic, anthelmintic, antibacterial
effects, and its oral administration is used for the treat-
ment of dysentery and vaginal discharge, while external
application is used for the treatment of eczema, psoria-
sis, and scabies [12,13]. In 1998, Yoo et al. discussed the
components of H. syriacus skin in depth [14]. However,
there are few references discussing its anti-cancer ef-
fects. Only a study in 2008 by Cheng et al. showed that
H. syriacus skin extract activated p53 and apoptosis-
inducing factor (AIF), which induced apoptosis in hu-
man lung cancer cells [15].
In this study, fifteen H. syriacus skin extracts were
screened, including seven crude extracts and eight pure
compounds. After treating estrogen receptor (ER)-negative
and triple-negative breast cancer cell lines with the ex-
tracts, functional assays were performed, which showed
cell viability-inhibitory effects. In addition, triterpenoids
(betulin and its derivatives) isolated from H. syriacus skin
activated the signaling pathway regulated by p53 family
genes, leading to the inhibition of breast cancer cell viabil-
ity or even the induction of apoptosis. And those triterpe-
noids had no effect on normal breast cells. These findings
provide an important basis for the use of those triterpe-
noids in the development of alternative therapies for breast
cancer treatment.Methods
Cell lines
Human breast cancer cell lines MDA-MB-231 and HBL-
100 were originally obtained from American Type Culture
Collection (ATCC, Manassas, VA). Non-tumorigenic
human breast epithelial cell line H184B5F5/M10 was
obtained from the Bioresource Collection and Research
Center (BCRC, Taiwan). MDA-MB-231 and HBL-100
were maintained in Dulbecco’s Modified Eagle medium
(DMEM) containing 10% fetal bovine serum, 1 μg/ml
penicillin and 1 μg/ml streptomycin (Invitrogen) at 37°C
in a 5% CO2 atmosphere. H184B5F5/M10 cells were
grown in MEM-α with the same supplements and culture
condition.
Plant material and compounds
The root bark of H. syriacus was obtained from Chien-Yuan
Co., Taipei, Taiwan, in September 2009, and the plant was
authenticated by Hang-Ching Lin from a voucher specimen
(NDMCP no. 980901). All compounds for screening were
offered by Professor Wen-Liang Chang, and the detailed
isolating approaches of those compounds are described
in reference [16].
Cell viability determined by MTT assay
Cells treated with the indicated concentrations of com-
pounds were washed twice with phosphate buffered saline
(PBS) and subjected to the 3-(4, 5-Dimethylthiazol-2-yl)-2,
5-diphenyl-tetrazolium bromide (MTT) assay to measure
proliferation. In brief, 20 μl of 5 mg/ml MTT reagent was
added to each well and incubated at 37°C for 3.5 h before
reading absorbance at 570 nm. A570 was recorded at 0 h,
24 h, 48 h, and 72 h after treatment. Each condition was
performed in six replicates. Cell morphology was visual-
ized under the indicated conditions by using an Olympus
CKX41 light microscope.
Migration assays
Wound healing assays were employed to evaluate the ef-
fects of those compounds on the cell migratory ability.
Cells were plated in 6-cm dishes and cultured to >90%
confluence. They were scraped with a p200 pipette tip
(time 0), transferred to low-serum culture medium, and
treated as indicated. The distances of migrating cells
were measured from pictures (five fields) taken at 0h,
12h, and 24h, and the distance of each measurement
was calculated by ImageJ (NIH, USA). Each experiment
was independently repeated at least three times.
Western blot analysis
Treated cells were washed twice with PBS, then lysed in
200 μl of RIPA lysis buffer (Millipore, 50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS) containing protease
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the supernatant was loaded on an SDS-polyacrylamide
gel, followed by western blot analysis (antibody informa-
tion is listed in Additional file 1: Table S2). The immuno-
reactive bands were revealed by an ECL system (Millipore)
then developed and quantified on a UVP BioSpectrum
Imaging System. Each band was quantified using ImageJ.
β-Actin used as internal (loading) control for relative
quantitation.
Data analysis
Real-time PCR original data, western blot data and
wound healing regions were recorded as continuous
variables and analyzed with Student’s t-test. All the
statistical analyses were performed using SPSS 16.0
and Excel 2010. All statistical tests and P values were
two-sided. The level of significance was set at P < 0.05.
Real-time PCR and flow cytometry
Detail methods of RNA preparation, quantitative real-time
PCR, and flow cytometry were described in Additional file 1.
Results
Toxicity analysis of H. syriacus extracts on breast cancer
cell lines
Seven crude extracts (100, 50, 25, 10, 1 μg/ml) and eight
pure compounds (10, 5, 2.5,1, 0.1 μg/ml) from H. syriacus
were used to treat invasive MDA-MB-231 and noninva-
sive HBL-100 breast cancer cell lines for 48 h before an
MTT assay was performed. HISY-F2, HISY-F3, and HISY-
F4 showed the best effects on both breast cancer cell lines.
The effects of these pure compounds on breast cancer cell
viability varied, including a poor inhibitory effect of K07,
K08, and K09 and a strong inhibitory effect of K01, K02,
K03, and K04. The inhibitory effect of K06 was the stron-
gest (Figure 1). In addition, based on the original analysis
of the pure compounds, the inhibition of cell viability by
the pure compound was consistent with that of the crude
extract. On the other hand, MDA-MB-231 cells showed a
stronger tolerance to drug treatment. Thus, the inhibitory
effect on MDA-MB-231 was poorer than that on HBL-
100 cells (Figure 1).
The results from the MTT assay showed that the in-
hibitory effects of K01, K02, K03, K04, and K06 on the
cell viability of breast cancer cell lines were the greatest.
However, they had non-significant effects on the cell via-
bility of the non-tumorigenic human breast epithelial
cell line H184B5F5/M10 (Additional file 1: Figure S5E).
Compound structural analysis showed that K01, K02,
K03, K04, and K06 were the derivatives of betulin
(Additional file 1: Figure S1), but the mechanism of ac-
tion of these compounds was unclear. Thus, we evalu-
ated the biological effects of betulin and its derivatives
on breast cancer cells.Betulin and its derivatives induce morphology changes in
breast cancer cell lines
After treating HBL-100 cells with 10 μg/mL of K02,
K03, K04, or K06 for 48 h, cell morphology was exam-
ined under microscopy. In the DMSO control group, the
cells were flat and adhered to the culture dish with high
cell density. However, the cells treated with those triterpe-
noids became long, slender, and spindle-and star-shaped.
In addition, the nucleus showed vacuolization, and the cell
density decreased (Figure 2). Thus, betulin and its deriva-
tives inhibited breast cancer cell viability and may have
induced breast cancer cell apoptosis.
Betulin and it derivatives induce breast cancer cell
apoptosis
To examine the cell cycle and proportion of sub-G1
phase cells in breast cells after treatment with betulin or
its derivatives, HBL-100 and H184B5F5/M10 cells were
treated with 10 μg/mL of K02, K03, K04 or K06 for
48 h, stained with PI and subjected to flow cytometry.
The cells treated with those triterpenoids showed a signifi-
cant increase in the proportion of cells in sub-G1 phase
compared to the DMSO control group. These results indi-
cate that betulin and it derivatives induced apoptosis in
breast cancer cells (Additional file 1: Figure S2). The
compounds had a relatively lower toxicity to the non-
tumorigenic human breast epithelial cell line H184B5F5/
M10 (Additional file 1: Figure S5F).
HBL-100 cells treated with 10 μg/mL of K02, K03,
K04 or K06 for 48 h were further double-stained with
Annexin V/PI for flow cytometry to determine the toxic
effects of betulin and its derivatives on breast cancer
cells. The results showed that >50% (the sum of the first
and fourth quadrant) of cells were apoptotic after K06
treatment, approximately 40% were apoptotic after K02
treatment, and approximately 25% of cells were apop-
totic after K03 or K04 treatment. Overall, apoptosis was
significantly increased in the drug-treated groups com-
pared with DMSO control cells (2.06% apoptotic cells)
(Additional file 1: Figure S3). And K02 and K06 pos-
sessed a greater ability to induce apoptosis than K03 and
K04.
Betulin and it derivatives inhibit migration of breast
cancer cells
A wound healing assay was performed to observe the ef-
fect of betulin and its derivatives on the migration ability
of breast cancer cells. After treating invasive MDA-MB-
231 cells with 5 μg/mL (about IC25was used to reduce
the interference of apoptosis) of K02, K03, K04,or K06
for 24 h, wound healing status was determined under
the same field every 12 h. In the DMSO control group,
the wound area was almost healed at 24 h. The wound
areas of K02-, K03-, K04-, or K06-treated cells were
Figure 1 The effect of H. syriacus skin crude extracts and pure compounds on the cell viability of MDA-MB-231 and HBL100 cell lines.
MDA-MB-231(A) and HBL100 (B) were treated with 0, 1, 10, 25, 50, or 100 μg/mL crude extracts for 48 h and subjected to MTT assay to analyze
the cell viability of MDA-MB-231 and HBL100 cell lines. (A) MDA-MB-231 cells treated with 100 μg/ml HISY-F2 or HISY-F3 showed 20% cell viability
compared with DMSO controls (0.1% DMSO). MDA-MB-231 cells treated with 50 μg/mL of HISY-F3 crude extract showed a cell viability of <50%
compared with DMSO controls. (B) Cell viability of HBL-100 cells treated with 50 μg/mL of HISY-F2 or HISY-F3 was 20% of DMSO controls, and
the cell viability of HBL-100 cells treated with 100 μg/mL of HISY-F2 or HISY-F3 was less than 20% of that of DMSO controls. (C) Cell viability decreased
by 5 μg/mL treatment with K01, K02, K03, K04, or K06 compared with DMSO controls; 10 μg/mL of K02 or K06 reduced cell viability to <50% compared with
DMSO controls. (D) Cell viability decreased by 1 μg/mL treatment with K01, K02, K03, K04, or K06 compared with DMSO controls; 10 μg/mL of K01, K02, K03,
K04 or K06 reduced cell viability to <50% compared with DMSO controls.
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trols (Figure 3 upper). After quantifying the wound areas
with ImageJ, the results showed that this region shrank
faster in the DMSO control compared to the K02-, K03-,
K04-, or K06-treated groups. Thus, betulin and it deriva-
tives inhibited the migratory ability of breast cancer cells,
especially K02 and K06 (Figure 3 lower).
Betulin and its derivatives induce apoptosis in breast
cancer cells was related to TAp63
The H. syriacus skin extracts K02 and K06 induced
apoptosis in MDA-MB231 cells. Betulin and betulinic
acid can induce cancer cell death via intrinsic apoptotic
pathways [17,18]. Furthermore, H. syriacus skin extracts
activate p53 and AIF, leading to lung cancer cell apoptosis[15]. After treating cells with 10 μg/mL of K02, K03, K04
or K06 for 12, 24, or 36 h, we performed real-time PCR to
analyze the apoptosis-related genes BAX, NOXA, PERP,
and PUMA, and the p63 isoforms ΔNp63 and TAp63. p63
is one member of the p53 tumor suppressor gene family,
and it is highly similar to p53 in protein structure. Based
on the sequence at the N-terminal end of the protein, p63
is classified into two isoforms, ΔNp63 and TAp63 [19,20].
ΔNp63 and TAp63 antagonize each other in the regula-
tion of gene expression. For example, ΔNp63 inhibits
TAp63-regulated p53 downstream gene expression [19,20]
and promotes anti-apoptotic gene expression. After treat-
ing with K02 and K06 for 12 h, TAp63 was significantly
increased at 24 h and slightly decreased at 36 h. The
TAp63 antagonist ΔNp63 also increased at 12 h and
Figure 2 Betulin and its derivatives cause morphological
changes in HBL100 cells. After treating HBL-100 cells with 10 μg/mL
of K02 (B), K03 (C), K04 (D) or K06 (E) for 48 h, cell morphology changed
to star-shaped and linear-shaped with vacuolation, and cell density
significantly decreased. In the DMSO control group (A, 0.1%
DMSO), cell shapes were intact and flat with higher density.
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of the TAp63 downstream apoptotic genes, including
BAX, NOXA, PUMA and PERP, increased over time
(Additional file 1: Figure S4A and 4D). These results imply
that K02 and K06 induced apoptotic gene expression is
TAp63 associated in the MDA-MB-231 cell line. Although
K03 and K04 treatment also increased TAp63 expression,
no significant change was observed in ΔNp63 or down-
stream apoptotic genes (Additional file 1: Figure S4B and
4C). Therefore, in p53-mutated MDA-MB-231 breast can-
cer cells, K02 and K06 may induce TAp63 expression to
compensate for parts of p53 function.
After treating HBL-100 cells with 10 μg/mL of K02,
K03, K04 or K06 for 12, 24, or 36 h, the pro-apoptotic
protein Bax significantly increased at 36 h, and the anti-
apoptotic gene Bcl-x slightly decreased over time, though
without significance. Cleaved caspase-3 and cleaved PARP
gradually increased after treated with those triterpenoids;
K02 and K06 induced significantly higher cleaved caspase-
3 after 12 h and higher cleaved PARP at 36 h (Figure 4A).
Furthermore, K02, K06, K03 and K04 treatment induced
higher p53 and its downstream protein p21, whereas
p-AKT was downregulated. Especially, K02 and K06
significantly induced p53 and p21 and reduced p-AKT
(Figure 4B). These results indicate that betulin and its de-
rivatives induced HBL-100 cell apoptosis by increasing
Bax, cleaved caspase-3 and cleaved PARP and decreasing
Bcl-x; and they inhibited HBL-100 cell growth by termin-
ating the cell cycle by increasing p53 and p21 and decreas-
ing AKT phosphorylation (Figure 4). K02 and K06 showed
stronger activity for the induction of apoptotic and cell
cycle inhibitory genes than the other compounds. In the
MDA-MB231 cell, the p53 gene was mutated. Thus, it
was necessary to clarify the molecular mechanism how
those triterpenoids induced apoptosis in this cell line. It isevident that p53-related apoptotic genes are also regulated
by p63 [21], and therefore p63 may participate in those tri-
terpenoids induced apoptosis in MDA-MB-231 cell.
Real-time PCR was performed to analyze ΔNp63 and
TAp63 RNA expression. After treatment with K02 or
K06 for 12 h, TAp63 significantly increased at 24 h and
slightly decreased at 36 h. ΔNp63 also increased at 12 h,
but it lost significance or returned close to baseline at
24 h or 36 h. Although K03 and K04 treatment also in-
creased TAp63 expression, ΔNp63 expression showed
no significant changes. These results indicate that in the
MDA-MB-231 cell, K02 and K06 induced apoptotic gene
expression in a TAp63-associated manner. Although K03
and K04 treatment increased TAp63 expression, no increase
in downstream gene expression was observed (Additional
file 1: Figure S4). Thus, in p53-mutated MDA-MB-231
breast cancer cells, K02 and K06 may induce TAp63 expres-
sion to compensate parts of p53 function. In the non-
tumorigenic human breast epithelial cell, H184B5F5/M10,
the expression of BAX, NOXA, PUMA and PERP showed
no change with K02, K03, K04 or K06 treatment, whereas
TAp63 decreased with treatment time and ΔNp63 expres-
sion fluctuated (Additional file 1: Figure S5A-D).
Discussion
Accumulating evidence demonstrates that induction of
apoptosis in cancer cells is the major effect of chemo-
therapy [9,15]. In this study, betulin and its derivatives
also induced human breast cancer cell apoptosis, and
there were different susceptibilities between the cell lines.
For instance, betulin (K02) and betulinic acid (K06) led to
higher apoptosis in HBL-100 than MDA-MB-231 cells
(Figure 1C and 1D). Dysregulated apoptosis is typically
observed in cancer cells; however, betulin derivatives regu-
lated different apoptotic proteins in different cancer types
[10,11,17]. In the present study, betulin (K02) and betuli-
nic acid (K06) had different IC50 values between HBL-100
and MDA-MB-231 cells (Figure 1A and 1B). Because
MDA-MB-231 is a p53-mutant cell line and HBL-100 is a
p53-wild-type cell line, we found that MDA-MB-231 cells
induced the tumor suppressor TAp63 in a compensatory
manner. TAp63 is a highly conserved member of the p53
family that is structurally similar to p53; therefore, it was
able to induce apoptosis by activating p53 downstream
target genes, including BAX, NOXA, PUMA, and PERP
(Additional file 1: Figure S4) [21-23]. TAp63 can also in-
duce p21 expression and has been associated with cell
cycle arrest and apoptosis [24,25].
In addition, K03 and K04 betulin derivatives induced a
lower level of apoptosis than K02 and K06 (Additional
file 1: Figure S2); however, K03 and K04 caused G2/M
arrest, as shown by flow cytometry. Furthermore, K03
and K04 repressed cell migration in wound healing as-
says (Figure 3).
Figure 3 (See legend on next page.)
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Figure 3 Betulin and its derivatives inhibit cell migration in the MDA-MB-231 cell line. A wound healing assay was performed to determine the cell
migration ability. MDA-MB-231 cells were treated with 0.1% DMSO (A, B, C) or 5 μg/mL K02 (D, E, F), K03 (G, H, I), K04 (J, K, L), or K06 (M, N, O) for 24 h.
The cells were observed every 12 h under the same observation field for wound healing status. At 12 h, cell migratory abilities in K03- (H) and K04-
treated (K) cells slightly decreased compared with DMSO controls (B). In K02- (F) and K06-treated (N) cells, cell migratory abilities more obviously
decreased compared with DMSO controls (B). At 24 h, cell migratory abilities in the K02 (L), K03 (H), K04 (K), and K06 (O) groups significantly
decreased compared with DMSO controls (B), and the wound area was larger than that of DMSO controls (C). The wound area was quantified by
ImageJ software. Compared with 12 h of DMSO treatment, the wound area was slightly significantly larger (* p < 0.05) in the K03- and K04-treated
groups and more significantly larger in the K02- and K06-treated groups (** p < 0.01). Compared with 24 h of DMSO treatment, the wound area was
significantly larger (# p < 0.05) in the K03- and K04-treated groups and also significantly larger in the K02- and K06-treated groups (## p < 0.01).
Hsu et al. BMC Complementary and Alternative Medicine  (2015) 15:65 Page 7 of 9Basal-like breast cancer is generally triple-negative
(ER-negative, PR-negative, and Her2/neu-negative), with
a similar gene expression profile to myoepithelial cells
[26]. However, it remains difficult to clearly distinguish
basal-like breast cancer from triple-negative breast cancerFigure 4 K02, K03, K04, and K06 induce the expression of apoptosis-r
cells with 10 μg/mL of K02, K03, K04, or K06 for 0, 12, 24, or 36 h, western
used as the internal control for relative quantitation. Cleaved caspase-3 inc
under K02 and K06 treatment. Cleaved PARP also increased with treatment
was significantly increased at 36 h with all four compounds. Bcl-x expressio
treating HBL-100 cells with 10 μg/mL of K02, K03, K04, or K06 for 0, 12, 24,
total AKT. p53 and p21 expression were induced after treatment with K02,
p-AKT progressively decreased after treatment with K02 and K06, while total A[27]. Clinically, triple-negative breast cancer possesses
higher invasiveness, more distal metastasis and poor prog-
nosis [28]. The BRCA1 tumor suppressor participates in
DNA repair and is often mutated in triple-negative breast
cancers [29]. The basal-like breast cancer gene expressionelated genes in the HBL-100 cell line. (A) After treating HBL-100
blot was performed to analyze apoptosis-related proteins. β-Actin was
reased with treatment time to a peak at 24 h and decreased at 36 h
time to a peak at 24 h under K02 and K06 treatment. Bax expression
n decreased with treatment time, though without significance.(B) After
or 36 h, western blot was performed to analyze p53, p21, p-AKT and
K03 or K06 and increased with treatment time with all four compounds.
KT showed no changes.
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shown by microarray [30] and immunohistochemical ana-
lysis [31], particularly in early-onset or familial breast can-
cer, and it is usually accompanied by a p53 mutation.
Several studies have addressed the association between
p53 and anthracycline treatment [32,33], and p53 func-
tions as a prognostic indicator of triple-negative breast
cancer therapeutic efficacy [34]. We employed two triple-
negative breast cancer cell lines, MDA-MB-231 and
HBL100 [35], to investigate the regulatory mechanism
of H. syriacus extracts on cell proliferation and apop-
tosis. Therefore, H. syriacus extracts or betulin and its
derivatives may function as potential adjuvant treat-
ments in p53-mutant cancers [36,37].
Conclusions
In this study, we have described four major findings: (1)
the natural compound betulin (K02) and its derivatives
(K03, K04, K06) induced human breast cancer cell apop-
tosis and inhibited cell proliferation; (2) K02 (betulin)
and K06 (betulinic acid) induced apoptotic protein ex-
pression, including BAX, NOXA, PUMA and PERP, and
also increased caspase-3 cleavage as well reduced the
anti-apoptotic gene Bcl-x in MDA-MB-231 and HBL-
100 cells; (3) K02 and K06 induced TAp63 in the p53-
mutant MDA-MB-231 cell line, leading top53-related
apoptosis; (4) betulin and its derivatives induced p21
activation and promoted cell cycle arrest.
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Figure S4. Betulin and its derivatives regulated apoptotic-related gene
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